$PFE News

Pfizer’s ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma

Pfizer Rose Nearly 21% in 2026 as Its Forward P/E Climbed From About 9 to 11 Times. Here’s What November 3 Has to Show

Pfizer (PFE) Stock Looks Above Fair Value As 30% Run Continues

Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting

Reported Saturday, Pfizer Presents Phase 2 25vPnC Infant Data At IDWeek 2026: Robust Responses To All 25 Serotypes, Including Five New, Safety Comparable To PREVNAR 20, No Related Serious Adverse Events

Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026

Pfizer's Dividend Yield Is One of the Highest in the S&P 500. Here's Why the Dividend Is Safer Than It Might Seem

Is Pfizer (PFE) Cheap As Its Enodia Deal Fuels Oncology Growth Hopes?

How To Boost The Dividend Yield On This Drugmaking Behemoth

Pfizer (PFE) Signs New Drug Discovery Pact Focused On Sec61 Inhibitors

Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing

Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It

What Pfizer Bulls Got Right

Pfizer's Stock Is Finally Showing Signs of Life. Could This Be the Start of a Much Bigger Rally?

Pfizer’s Dividend Freeze Raises a Bigger Question About Its Cash Flow

Bristol Myers is Cheaper Than Pfizer, but Its 40% Earnings Jump Has a Catch

Pfizer Just Declared Its 352nd Straight Quarterly Dividend. Is the 6% Yield Safe?

Pfizer vs. AbbVie: Is the Cheaper Pharma Stock Really the Better Investment?

What to Expect From Pfizer's Q3 2026 Earnings Report

Tukysa Approval Might Change The Case For Investing In Pfizer Stock (PFE)